Feedback
Settings

Settings

Goto Application

42 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(WARUUAMZJXEUEA-ZOQUXTDFSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 5
1.121729225具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
CN - 24.03.2026
Int.Class A61K 9/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
 Appl.No 202480054649.3 Applicant 埃泽瑞斯公司 Inventor E·贝古因
本发明提出了用具有特定特征的表面活性剂增强的新型脂质和类脂质纳米颗粒(LNP和LiNP)制剂。这些表面活性剂表现出独特的朗缪尔等温线特性，确保了纳米颗粒的最佳稳定性。所述制剂提高了稳定性，减少了聚集，并缓解了在纯化期间面临的挑战，比如过滤堵塞或结垢。该创新所必需的是基于预定的朗缪尔等温线值和过滤速度确定表面活性剂作为稳定剂的适用性的方法。当与治疗剂一起配制时，稳定的纳米颗粒在医学应用，特别是在mRNA递送、疫苗接种和免疫领域中具有证实的潜力。
2.20260062697MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS
US - 05.03.2026
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 19068961 Applicant ModernaTX, Inc. Inventor Melissa J. MOORE

The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.

3.2025529925安定な脂質またはリピドイドナノ粒子懸濁液
JP - 09.09.2025
Int.Class A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
 Appl.No 2025512010 Applicant エスリス　ゲーエムベーハー Inventor ドーメン，クリスチャン
安定化されている脂質ナノ粒子（ＬＮＰ）／リピドイドナノ粒子（ＬｉＮＰ）製剤およびＬＮＰ／ＬｉＮＰ懸濁液、それらの使用、ならびにサーファクタントを製剤または懸濁液に添加すると凝集が回避され、驚くほど長い貯蔵寿命および振とうに対する長期的な安定性が可能になるという知見に基づく処置の方法における使用が提供される。本発明による凝集の前記低減は、本発明の製剤および懸濁液の副作用の低減、具体的には、ＬＮＰおよび／またはＬｉＮＰを含むワクチン製剤および抗がん製剤によって引き起こされる副作用の低減をもたらす。
4.120285155IFN-λmRNA治疗病毒感染的用途
CN - 11.07.2025
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
 Appl.No 202510472800.1 Applicant 埃泽瑞斯公司 Inventor C·鲁道夫
本发明的名称是IFN‑λmRNA治疗病毒感染的用途。本发明涉及包括编码IFN‑λ多肽的mRNA的药物组合物，用于治疗病毒诱导的疾病，优选是病毒诱导的呼吸系统疾病，如COVID‑19。
5.120129532稳定的脂质或类脂质纳米颗粒悬浮液
CN - 10.06.2025
Int.Class A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols ; Poloxamers; PEG/POE alkyl ethers
 Appl.No 202380072045.7 Applicant 埃泽瑞斯公司 Inventor C·多曼
本发明提供了稳定的脂质纳米颗粒(LNP)/类脂质纳米颗粒(LiNP)制剂和LNP/LiNP悬浮液、其用途以及在治疗方法中的用途，其依据是发现在制剂或悬浮液中添加表面活性剂避免了聚集，使其具有惊人的长保质期和延长的振荡稳定性。根据本发明，所述聚集的减少降低了本发明制剂和悬浮液的副作用，特别是降低了由包括LNP和/或LiNP的疫苗制剂和抗癌制剂引起的副作用。
6.118949075Treatment of ciliary disease
CN - 15.11.2024
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No 202411027869.5 Applicant ETHRIS GMBH Inventor RUDOLPH CARSTEN
The present disclosure relates to the treatment of ciliary disease. The present disclosure provides a pharmaceutical composition comprising a polyribonucleotide for use in the treatment of ciliary disease in a subject suffering from ciliary disease wherein the polyribonucleotide encodes a functional version of a protein whose deficiency is associated with said ciliary disease, and wherein the pharmaceutical composition is administered to the respiratory system of a subject when the subject exhibits inflammation of the respiratory system. Further, the present disclosure relates to a method for analyzing the effect of a polyribonucleotide on ciliary formation, where the polyribonucleotide encodes a protein necessary to participate in ciliary formation and/or ciliary formation.
7.20240200078MICRORNA-DEPENDENT MRNA SWITCHES FOR TISSUE-SPECIFIC MRNA-BASED THERAPIES
US - 20.06.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 18056961 Applicant Cornell University Inventor Seyed Hani Najafi-Shoushtari

Synthetic 5′UTR sequences comprising miRNA binding sites that allow for enhanced translation efficiencies of linked open reading frames, vectors having the synthetic sequences linked to an open reading frame and methods of using isolated mRNA and vectors with the synthetic sequences linked to an open reading frame, are provided.

8.20240165267MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF
US - 23.05.2024
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No 18058656 Applicant ModernaTX, Inc. Inventor Atanu ROY

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

9.117729930Use of IFN-Lambda mRNA to treat viral infections
CN - 19.03.2024
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No 202180074507.X Applicant ETHRIS GMBH Inventor RUDOLPH CARSTEN
The present invention relates to a pharmaceutical composition comprising an mRNA encoding an IFN-lambda polypeptide for use in the treatment of a virus-induced disease, preferably a virus-induced respiratory disease, such as COVID-19.
10.2024507394エアロゾル形成用の製剤および核酸を送達するためのエアロゾル
JP - 19.02.2024
Int.Class A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
 Appl.No 2023551966 Applicant エスリス　ゲーエムベーハー Inventor ドーメン，クリスティアン
本発明は、ビヒクル水溶液に懸濁されている脂質またはリピドイドナノ粒子を含むエアロゾル形成用の水性懸濁製剤であって、脂質またはリピドイドナノ粒子が、以下の構成成分（ａ）および（ｂ）：（ａ）核酸、および（ｂ）イオン化可能な脂質またはイオン化可能なリピドイドを含み、ビヒクル水溶液が、１つのポリ（プロピレンオキシド）ブロックおよび２つのポリ（エチレンオキシド）ブロックを含有するトリブロックコポリマーを含む、水性懸濁製剤に関する。さらに、本発明は、エアロゾル形成用の製剤から得られるエアロゾルに関する。
# -